Familial combined hyperlipidemia (FCHL) is the most common atherogenic disorder of lipid metabolism [1, 2], typically characterized by multiple hyperlipemic phenotypes within the same individual as well as in the same family, where elevated very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) or apolipoprotein B (apoB) can be detected [3–5]. This evidence concerns the gene APOB and metabolic process.